Home About Shands For Healthcare Professionals Newsroom ShandsConnect Index
Search:

Hypercoagulable states

Coordinated Cancer Care at Shands at UF
The coordinated cancer care programs at Shands at the University of Florida provide patients with streamlined access to comprehensive and compassionate care, cutting-edge treatment options and novel clinical trials. Schedule an appointment with one of the coordinated cancer care programs or learn more about the UF Gastrointestinal Oncology Program, UF Genitourinary Oncology Program and the UF Breast Center.

Definition

Hypercoagulable states are conditions that may lead to the abnormal development of blood clots. Blood clots can develop in either arteries or veins.

See also:

Alternative Names

Thromboembolic states; Factor V Leiden; Prothrombin mutation 20210A

Causes

Hypercoagulable states fall into two groups:

  • Inherited
  • Acquired

Inherited means you are born with the tendency to form abnormal blood clots. Common inherited conditions that affect clotting are factor V Leiden and the prothrombin mutation 20210A. Rare inherited conditions include protein C, protein S, and antithrombin III deficiencies.

Acquired means you develop it later in life. Some medical situations can lead to the formation of abnormal blood clots. These include cancer, recent surgery or trauma, obesity, liver or kidney disease, and use of certain medications.

Conditions that can lead to the formation of blood clots include prolonged bedrest, dehydration, poor positioning (such as crossing the legs), sitting for long periods (such as in a plane or car), and long-term use of an intravenous catheter.

In women, birth control pills or hormone replacement therapy increase the risk of blood clots, and the risk is greatly increased in those who also smoke. The time before, during, and after pregnancy also increase the risk of clots.

References

Bauer K. Hypercoagulable states. In: Hoffman R, Benz EJ, Shattil SS, et al. Hematology: Basic Principles and Practice. 4th ed. Orlando, Fl: Churchill Livingstone; 2005:chap 127.


Review Date: 6/10/2008
Reviewed By: Sean O. Stitham, MD, private practice in Internal Medicine, Seattle, Washington; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com